Vor Biopharma shares rise 5.24% in after-hours after securing $175M in private funding and licensing telitacicept for autoimmune disease treatment.

Vor Biopharma Inc. surged 5.24% in after-hours trading, following the company's announcement of a $175 million private placement and a global licensing agreement with RemeGen for telitacicept to treat autoimmune diseases. The company also shifted its strategic focus to autoimmune disease treatments, with the new funding supporting business expansion.